The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.
The survival response of human colorectal carcinoma cells treated in vitro for 1 h with PCNU was characterized by a threshold exponential curve, Dq = 8 micrograms/ml (1 h) and Do = 22 micrograms/ml (1 h). Continuous treatment induced decreasing degrees of cell kill although PCNU was biologically stable in solution for at least 24 h. Cells treated with PCNU were unable to recover from potentially lethal damage but were quite capable of repairing PCNU-induced sublethal damage. Thus, PCNU with different alkylating and carbamoylating than other nitrosourea congeners had similar cytotoxic and repair inhibition capacities. Any therapeutic gain in the clinical use of PCNU must derive only from its lipophilic properties and not from its superior activity at the cellular level.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy; D004260:DNA Repair / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D009607:Nitrosourea Compounds / Q000494:pharmacology* / Q000633:toxicity; D012004:Rectal Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea